We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for amifampridine (ORSPEC Pharma Pty Ltd)
Active ingredients
amifampridine
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
RUZURGI is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above.
Therapeutic area
Neurology